GSK’s Advil Dual Action in Combination with Acetaminophen Receives the US FDA’s Approval for Pain Relief

GSK Reports Submission of NDA to MHLW for Daprodustat to Treat Patients with Renal Anaemia due to Chronic Kidney Disease in Japan


  • The approval is based on seven clinical studies including three of which were pivotal efficacy and safety studies in pain relief which involves assessing of ibuprofen (250 mg) + acetaminophen (500 mg) vs ibuprofen and acetaminophen monothx in patients with acute pain symptoms
  • The study demonstrated that the FD combination achieved superior efficacy then the monotherapy in patients
  • Advil Dual Action is combination of ibuprofen and acetaminophen resulting to an exclusive pain reliever and will be available over-the-counter nationwide in 2020

Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox